Study procedures
DISEASE
Participants initially received palbociclib 125 mg by mouth daily for 21 days and ganitumab 18 mg/kg intravenously on Days 1 and 15 in 28‐day cycles. Standard hematologic requirements were used as starting criteria. Participants were permitted to remain on therapy for up to 12 cycles in the absence of meeting off‐therapy criteria. Disease was assessed at baseline, during cycles 2, 4, 6, 8, 10, and 12 and at end of treatment.